Skip to main content

Table 3 Cox models for DFS and OS (univariate analysis)

From: Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy

 

Univariate analysis - DFS

Univariate analysis - OS

Variable

HR

95% CI

p

HR

95% CI

p

Age (per years)

1.01

0.99

1.04

0.270

1.05

1.01

1.08

0.005

ER- PgR-

1 (reference)

1 (reference)

ER+ PgR- / ER- PgR+

0.72

0.40

1.30

0.273

0.64

0.30

1.40

0.269

ER+ PgR+

0.51

0.29

0.89

0.018

0.51

0.25

1.04

0.066

Stage I

1 (reference)

1 (reference)

Stage II

2.01

1.13

3.56

0.018

3.73

1.48

9.41

0.005

Stage III

3.77

2.01

7.08

<0.001

9.77

3.85

24.82

<0.001

LN (pos vs. neg)

1.79

1.11

2.88

0.016

2.61

1.37

4.98

0.004

HER2 (pos vs. neg)

1.51

0.75

3.04

0.251

1.67

0.70

3.97

0.248

GSTT1 (null vs. present)

1.68

0.99

2.86

0.053

2.22

1.17

4.24

0.015

GSTM1 (present vs. null)

1.23

0.77

1.98

0.383

1.68

0.90

3.12

0.103

RFC1 – AA

1 (reference)

1 (reference)

RFC1 – GA

2.35

1.09

5.07

0.029

1.95

0.73

5.22

0.184

RFC1 – GG

2.89

1.31

6.38

0.009

2.90

1.07

7.88

0.036

GSTP1 – AA

1 (reference)

1 (reference)

GSTP1 – AG

0.77

0.46

1.26

0.297

-

-

-

0.989

GSTP1 – GG

-

-

-

0.985

0.80

0.42

1.53

0.500

MTHFR – CC

1 (reference)

1 (reference)

MTHFR – CT

1.28

0.72

2.27

0.394

1.02

0.49

2.13

0.957

MTHFR – TT

0.85

0.42

1.71

0.642

0.96

0.41

2.25

0.920

TS-TR – 2R/2R

1 (reference)

1 (reference)

TS-TR – 2R/3R

0.62

0.35

1.11

0.105

0.67

0.31

1.48

0.327

TS-TR – 3R/3R

0.80

0.46

1.41

0.439

1.11

0.54

2.28

0.767

Combined genotype groups*

  

Group 1

1 (reference)

1 (reference)

Group 2

4.20

1.52

11.56

0.006

4.54

1.09

18.92

0.038

Group 3

6.61

1.93

22.59

0.003

10.12

2.04

50.19

0.005

  1. HR Hazard Ratio, CI Confidence Interval, DFS Disease free Survival, OS Overall Survival, LN lymph nodes
  2. *group1: GSTT1-present and RFC1-AA
  3. group2: GSTT1-present and RFC1-GA/RFC1-GG or GSTT1-null and RFC1-GA/RFC1-AA
  4. group3: GSTT1-null and RFC1-GG
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us